Research graph
References from Dabigatran Attenuates Osteoporosis by Balancing Osteoblastogenesis and Osteoclastogenesis by Targeting PRKAB1 and RELA. Local targets link to admitted publications; unresolved targets remain external evidence.
Recent advances in osteoporosis therapeutics
10.1146/annurev-med-050124-040555 · 2026 · External reference
Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: A systematic analysis from the Global Burden of Disease Study 2019
10.1016/s2666-7568(21)00172-0 · 2021 · External reference
Treatment of osteoporosis and osteoarthritis in the oldest old
10.1007/s40265-024-02138-w · 2025 · External reference
Consequences of aging on bone
2023 · External reference
Posttranslational modification in bone homeostasis and osteoporosis
10.1002/mco2.70159 · 2025 · External reference
Targeting the gut microbiota-related metabolites for osteoporosis: The inextricable connection of gut-bone axis
10.1016/j.arr.2024.102196 · 2024 · External reference
10.1038/s41413-023-00296-3
10.1038/s41413-023-00296-3 · External reference
OTUD1 inhibits osteoclast differentiation and osteoclastic bone loss through deubiquitinating and stabilizing PRDX1
10.7150/thno.111360 · 2025 · External reference
Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway
10.1016/j.phymed.2025.156429 · 2025 · External reference
Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials
10.1136/bmj-2021-068033 · 2023 · External reference
Mechanistic advances in osteoporosis and anti-osteoporosis therapies
10.1002/mco2.244 · 2023 · External reference
Interventions for managing medication-related osteonecrosis of the jaw
2022 · External reference
Considerations regarding the use of romosozumab in a patient at high risk for cardiovascular disease
10.1093/jbmr/zjaf164 · 2026 · External reference
Healthcare and productivity cost of osteoporosis: A Danish register-based quasi-experimental study
10.1007/s00198-025-07453-w · 2025 · External reference
The global, regional, and national burden attributable to low bone mineral density, 1990-2020: An analysis of a modifiable risk factor from the Global Burden of Disease Study 2021
10.1016/s2665-9913(25)00105-5 · 2025 · External reference
Gut microbiota and bone aging: Focusing on the gut-X axis modes
10.1016/j.jot.2026.101064 · 2026 · External reference
10.1080/10408398.2022.2047005
10.1080/10408398.2022.2047005 · External reference
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies
10.1016/j.pharmthera.2023.108383 · 2023 · External reference
Structures and biological activities of anti-osteoporotic drugs: An overview of promising small-molecule therapeutics for the treatment of osteoporosis
10.1016/j.bioorg.2025.108568 · 2025 · External reference
Perioperative management of patients taking direct oral anticoagulants: A review
10.1001/jama.2024.12708 · 2024 · External reference
Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists
10.1093/ehjcvp/pvaa094 · 2021 · External reference
The association of non-vitamin K antagonist oral anticoagulants vs. warfarin and the risk of fractures for patients with atrial fibrillation: A systematic review and meta-analysis
10.1080/00015385.2022.2030555 · 2023 · External reference
10.1111/iej.13447
10.1111/iej.13447 · External reference
10.1038/s41422-024-01016-0
10.1038/s41422-024-01016-0 · External reference
10.1080/15548627.2023.2186112
10.1080/15548627.2023.2186112 · External reference
10.1038/s41418-022-01028-6
10.1038/s41418-022-01028-6 · External reference
A SPLICS reporter reveals α-synuclein regulation of lysosome-mitochondria contacts which affects TFEB nuclear translocation
10.1038/s41467-024-46007-2 · 2024 · External reference
10.1038/s41586-022-05652-7
10.1038/s41586-022-05652-7 · External reference
10.1080/15548627.2021.1886839
10.1080/15548627.2021.1886839 · External reference
10.1016/j.semcancer.2024.08.002
10.1016/j.semcancer.2024.08.002 · External reference
Drug therapy for osteoporosis in older adults
10.1016/s0140-6736(21)02646-5 · 2022 · External reference
FABP4 inhibition suppresses bone resorption and protects against postmenopausal osteoporosis in ovariectomized mice
10.1038/s41467-025-59719-w · 2025 · External reference
10.1038/s41422-023-00918-9
10.1038/s41422-023-00918-9 · External reference
The global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990-2019
10.3389/fendo.2022.882241 · 2022 · External reference
Osteoporosis treatment: Current drugs and future developments
10.3389/fphar.2024.1456796 · 2024 · External reference
Bisphosphonates
10.1136/bmj-2023-076898 · 2024 · External reference
Indications and adverse events of teriparatide: Based on FDA adverse event reporting system (FAERS)
10.3389/fphar.2024.1391356 · 2024 · External reference
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system
10.1038/s41598-023-37944-x · 2023 · External reference
Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
10.1001/jama.2017.1363 · 2017 · External reference
Autophagic damage in senescent bone marrow mesenchymal stromal cells: Impact on Piezo1 expression during osteoporosis progression
10.1016/j.ijbiomac.2025.147928 · 2025 · External reference
Restrained Mitf-associated autophagy by mulberroside A ameliorates osteoclastogenesis and counteracts OVX-induced osteoporosis in mice
10.1038/s41420-024-01847-1 · 2024 · External reference
Osteoporosis remission via an anti-inflammaging effect by icariin activated autophagy
10.1016/j.biomaterials.2023.122125 · 2023 · External reference
10.1080/15548627.2021.2016231
10.1080/15548627.2021.2016231 · External reference
10.1038/s41586-022-04431-8
10.1038/s41586-022-04431-8 · External reference
10.3390/cells10051095
10.3390/cells10051095 · External reference
10.1080/15548627.2021.1898748
10.1080/15548627.2021.1898748 · External reference
10.1080/15548627.2024.2355074
10.1080/15548627.2024.2355074 · External reference
10.1038/s41580-023-00641-8
10.1038/s41580-023-00641-8 · External reference
Hypoxia-preconditioned BMSC-derived exosomes induce mitophagy via the BNIP3-ANAX2 axis to alleviate intervertebral disc degeneration
10.1002/advs.202404275 · 2024 · External reference
Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-κB activated pyroptosis pathways
10.1016/j.phrs.2021.105967 · 2021 · External reference
Irisin alleviates obesity-induced bone loss by inhibiting interleukin 6 expression via TLR4/MyD88/NF-κB axis in adipocytes
10.1016/j.jare.2024.04.013 · 2025 · External reference
10.1038/s41392-024-01757-9
10.1038/s41392-024-01757-9 · External reference
10.1016/j.jmb.2017.02.017
10.1016/j.jmb.2017.02.017 · External reference
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
10.1161/circulationaha.110.004747 · 2011 · External reference
LRRc17 controls BMSC senescence via mitophagy and inhibits the therapeutic effect of BMSCs on ovariectomy-induced bone loss
10.1016/j.redox.2021.101963 · 2021 · External reference
Atsttrin regulates osteoblastogenesis and osteoclastogenesis through the TNFR pathway
10.1038/s42003-023-05635-y · 2023 · External reference
10.34133/research.0660
10.34133/research.0660 · External reference
10.1016/j.jare.2025.04.030
10.1016/j.jare.2025.04.030 · External reference
Lobetyolin suppressed osteoclastogenesis and alleviated bone loss in ovariectomy-induced osteoporosis via hindering p50/p65 nuclear translocation and downstream NFATc1/c-Fos expression
10.2147/dddt.s515930 · 2025 · External reference
Dendrobine attenuates osteoclast differentiation through modulating ROS/NFATc1/ MMP9 pathway and prevents inflammatory bone destruction
10.1016/j.phymed.2021.153838 · 2022 · External reference
DNMT aberration-incurred GPX4 suppression prompts osteoblast ferroptosis and osteoporosis
10.1038/s41413-024-00365-1 · 2024 · External reference
10.34133/research.0784
10.34133/research.0784 · External reference
GLUL mediates FOXO3 O-GlcNAcylation to regulate the osteogenic differentiation of BMSCs and senile osteoporosis
10.1038/s41418-025-01543-2 · 2025 · External reference
10.1016/j.cmet.2021.02.007
10.1016/j.cmet.2021.02.007 · External reference
Fexofenadine protects against osteoarthritis by targeting Smad2 and STAT1 to enhance anabolism and binding cPLA2 to inhibit catabolism
10.1038/s41420-025-02754-9 · 2025 · External reference
10.1136/annrheumdis-2021-221380
10.1136/annrheumdis-2021-221380 · External reference
10.1136/annrheumdis-2019-215543
10.1136/annrheumdis-2019-215543 · External reference
